Skip to content
Wenlo
Sign in
← Markets

Neurocrine Biosciences, Inc.

Kyle Gano (Chief Executive Officer) reports NBIX insider transactions

4NBIXFiled Nov 3, 2026, 12:59 PM ET· Period Nov 1, 2026

About this filing

Neurocrine Biosciences, Inc. (NBIX) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.

Key facts

Insider
Kyle Gano · Chief Executive Officer, Director
DateTransactionSharesPriceValueHeld afterOwnership
Nov 1, 2026M · exercise or conversion of a derivative+614$0.00$0.00155,342Direct
Nov 1, 2026F · tax withholdingFootnotes F1−332$146.10$48,505.20155,010Direct
Nov 1, 2026M · exercise or conversion of a derivativeRestricted Stock UnitFootnotes F2, F3−614$0.00$0.001,228Direct
Footnotes
  1. F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
  2. F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
  3. F3 This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.

More NBIX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.